34
Participants
Start Date
August 14, 2017
Primary Completion Date
October 17, 2019
Study Completion Date
June 12, 2020
Rozibafusp Alfa
Administered by subcutaneous injection once every 2 weeks.
Placebo
Administered by subcutaneous injection once every 2 weeks.
Charite Research Organisation GmbH, Berlin
Altoona Center for Clinical Research, Duncansville
Pinnacle Research Group LLC, Anniston
Metroplex Clinical Research Center, Dallas
Lead Sponsor
Amgen
INDUSTRY